Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cytosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.32 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL1144358 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL1629580 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL10496353 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL26123983 | 0.98 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL29123329 | 0.94 | TSHR (0.36) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL5356635 | 0.94 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL28199181 | 0.93 | DYRK1A (0.34) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL28004771 | 0.90 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL4059 | 0.89 | — | — | |
| Cytosine SCHEMBL1330400 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2516 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596713-A1 | DNA WITH ENHANCED RESISTANCE AGAINST EXONUCLEASES AND METHODS FOR THE PRODUCTION THEREOF | 4basebio UK Ltd (GB) | 2025-08-06 | — | — | EP | claimed |
| CN-115219716-B | Method for detecting carbendazim residue based on personal blood glucose meter | 西南大学 | 2025-03-18 | — | — | CN | claimed |
| WO-2024250923-A1 | CHEMICALLY MODIFIED NUCLEOSIDE, CHEMICALLY MODIFIED NUCLEOSIDE TRIPHOSPHATE AND USE THEREOF | 中国科学院深圳先进技术研究院 | 2024-12-12 | — | — | WO | claimed |
| WO-2024250607-A1 | CHEMICALLY MODIFIED CYTIDINE TRIPHOSPHATE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院深圳先进技术研究院 | 2024-12-12 | — | — | WO | claimed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | claimed |
| WO-2023115732-A1 | SINGLE-POT METHODS FOR PRODUCING CIRCULAR RNAS | PEKING UNIVERSITY (CN) | 2023-06-29 | — | — | WO | claimed |
| CN-116113419-A | Cyclic RNA compositions and methods | 奥纳治疗公司 | 2023-05-12 | — | — | CN | claimed |
| CN-115807083-A | Colorectal cancer gene mutation identification method, device and application | 复旦大学附属中山医院 | 2023-03-17 | — | — | CN | claimed |
| EP-4146285-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| CN-115052635-A | Circular RNA compositions and methods | 奥纳治疗公司 | 2022-09-13 | — | — | CN | claimed |
| EP-1032700-A1 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | New York Medical College (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000036151-A1 | A HETEROGENEOUS ASSAY FOR PYROPHOSPHATE DETECTION | LI-COR, INC. (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0695366-A4 | METHOD OF RANDOM AMPLIFICATION OF POLYMORPHIC DNA | F B INVESTMENTS PTY LTD (AU) | 1999-07-28 | — | — | EP | claimed |
| WO-1999006592-A9 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | NEW YORK MEDICAL COLLEGE (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1999006592-A1 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | NEW YORK MEDICAL COLLEGE (US) | 1999-02-11 | — | — | WO | claimed |
| US-5759821-A | Method of random amplification of polymorphic DNA | F B INVESTMENTS PTY LTD (AU) | 1998-06-02 | — | — | US | claimed |
| EP-0695366-A1 | METHOD OF RANDOM AMPLIFICATION OF POLYMORPHIC DNA | F B Investments Pty. Ltd. (AU) | 1996-02-07 | — | — | EP | claimed |
| EP-0676476-A1 | Isothermal strand displacement nucleic acid amplification | GEN-PROBE INCORPORATED (US) | 1995-10-11 | — | — | EP | claimed |
| WO-1995025180-A1 | ISOTHERMAL STRAND DISPLACEMENT NUCLEIC ACID AMPLIFICATION | GEN-PROBE INCORPORATED (US) | 1995-09-21 | — | — | WO | claimed |
| WO-1994024307-A1 | METHOD OF RANDOM AMPLIFICATION OF POLYMORPHIC DNA | FORBIO PTY. LTD. (AU) | 1994-10-27 | — | — | WO | claimed |